Skip to main content

Table 5 Clinical outcomes during follow-up period in the propensity score matched groups (249 pairs)

From: Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea

  EES R-ZES Adjusted HR* 95% CI P value
All cause death 4.9 (11) 3.7 (8) 1.833 0.678-4.957 0.232
Cardiac death 2.2 (5) 1.9 (4) 1.667 0.398-6.974 0.484
Any myocardial infarction 2.7 (5) 2.0 (4) 1.000 0.202-4.955 >0.999
 Target vessel 2.2 (4) 1.6 (3) 1.500 0.251-8.977 0.657
Target lesion revascularization 5.7 (10) 7.2 (16) 0.533 0.226-1.258 0.151
Target vessel revascularization 7.4 (14) 9.1 (20) 0.706 0.337-1.478 0.356
Any revascularization 22.3 (35) 18.6 (36) 0.833 0.490-1.417 0.501
Target lesion failure 8.4 (16) 8.6 (19) 0.875 0.427-1.793 0.715
Patient-oriented outcome 26.4 (46) 21.1 (42) 1.029 0.642-1.650 0.904
  1. * Hazard ratio was calculated with stratified Cox proportional hazard regression, values are hazard ratio of EES compared with R-ZES.
  2. Abbreviations: CI confidence interval, EES everolimus-eluting stent, HR hazard ratio, R-ZES Resolute zotarolimus-eluting stent.